BioAdvance — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Vittoriabiovittoriabio.cominJul 2021
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical DevicesPhiladelphia, US
Nicholas Siciliano(Director)inPreston Noon(Executive Officer)
BoardGeeta Vemuri(Executive Officer, Director)Bruce Peacock(Executive Officer, Director)Leon Moulder(Director)
Co-investorsAgent CapitalGlobal BioAccess Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.